Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$41.9MCash on Hand
107.5mo Cash Runway
Follow HOWL by emailGet an email when HOWL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HOWL, unsubscribe in one click. Privacy
📣 What HOWL Says Is Next
first quarter of 2027 · “The transaction is expected to close by the first quarter of 2027, subject to certain closing conditions, including the approval by the stockholders of each company, the shares of Werewolf Therapeutics common stock issuable in the transaction having been approved for listing on Nasdaq, effectiveness of the registration statement on Form S-4 (the “Form S-4”) and the satisfaction of other customary closing conditions.”
Company press release, Aug 21, 2026 · SEC filing
in 2028 · “Ambros Therapeutics anticipates reporting topline data from CRPS-RISE in 2028.”
Company press release, Aug 21, 2026 · SEC filing
in 2028 · “Ambros Therapeutics expects the combined company to be fully funded through topline results from the pivotal CRPS-RISE Phase 3 clinical trial expected in 2028 and a planned New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (“FDA”) for potential approval of neridronate in patients with CRPS-1, with cash runway into the first half of 2029.”
Company press release, Aug 21, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Deal Werewolf and Ambros Therapeutics agreed to merge, with Werewolf renamed Ambros Therapeutics. Ambros holders would own about 72.0% of the combined company, and a $150.0 million concurrent PIPE is planned. Stockholders vote December 17, 2026. Form 424B3 · SEC filing
Nov 9, 2026 ·
Clinical trial Werewolf reported new SITC 2026 data for WTX-124, an IL-2 INDUKINE, including one durable complete response in ICI-resistant cutaneous squamous cell carcinoma and an FDA-aligned recommended Phase 2 dose of 18 mg IV Q2W. It also reported WTX-330 (IL-12) data, including a confirmed partial response in gallbladder cancer. Form 8-K · SEC filing · Press release
Aug 21, 2026 ·
Deal Werewolf Therapeutics agreed to an all-stock merger with Ambros Therapeutics, with Ambros holders expected to own about 71.7% of the combined company. A concurrent $150 million private placement is expected to fund operations into 1H 2029, and the combined company will focus on neridronate for CRPS-1. Form 8-K · SEC filing · Press release
Aug 20, 2026 ·
Deal Werewolf sold its INDUCER and INDUKINE preclinical platforms to EMD Serono for $28.0 million upfront plus $5.0 million on completion of the technology transfer, keeping its WTX-124 and WTX-330 clinical programs. The company also agreed to a 24-month non-compete on certain tumor-target compounds. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2026 · Phase 1/2 · Results Expected · A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma Registry primary completion date, not a results date
Apr 2026 · Phase 1 · Results Expected · Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors Registry primary completion date, not a results date
Dec 2024 · Phase 1 · Results Expected · WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not HOWL's own candidates): Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
HOWL holds $41.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.2M/quarter from operations,
an estimated runway of 107.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:40 · Elevated
Cash runway 108 months
ATM program on file since May 2025 +15
Shelf registration (S-3, May 2025) +10
Going-concern doubt in the latest 10-Q +15We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these condensed consolidated financial statements are issued in this Quarterly Report.10-Q, Nov 2026
Share count 48,599,066 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full HOWL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HOWL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.